Results 111 to 120 of about 3,635,661 (309)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Decrypting cancer's spatial code: from single cells to tissue niches

Molecular Oncology, EarlyView.
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik, Shi Pan, Eloise Withnell, Hou Wang Lam, Maria Secrier   +4 more
wiley   +1 more source

Individualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposal [PDF]

, 2016
Theodore J. Iwashyna, Adam M. Deane
openalex   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Developing generic clinical trial animated explainer videos in the UK: results of a survey and case study

Trials
Background Animated short videos used to explain a concept or project are often called animated explainer videos (AEVs). AEVs can supplement or provide an alternative to participant information sheets as a means of giving information about clinical ...
Clare Calvert, Vicki S. Barber, Duncan Appelbe, Kirsty Sprange, Claire Nollett, Fiona Lugg-Widger, Samantha Tanner, Duncan B. Richards   +7 more
doaj   +1 more source

Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12) [PDF]

, 2012
Teresa Sanz‐Cuesta, Paloma González-Escobar, Rosario Riesgo-Fuertes, Sofía Garrido-Elustondo, Isabel del Cura-González, Jesús Martín‐Fernández, Esperanza Escortell‐Mayor, Francisco Rodríguez Salvanés, Marta García‐Solano, R. González, María Ángeles Martín-de la Sierra-San Agustín, Carmen Olmedo-Lucerón, María Luisa Sevillano Palmero, Carmen Mateo-Ruiz, Beatriz Medina-Bustillo, Antonio Valdivia-Pérez, Francisca García-de Blas-González, José Enrique Mariño-Suárez, Ricardo Rodríguez-Barrientos, Gloria Ariza-Cardiel, Luisa Cabello-Ballesteros, Elena Polentinos-Castro, Milagros Rico‐Blázquez, Ma Teresa Rodríguez-Monje, Sonia Soto-Díaz, Susana Martín‐Iglesias, Ramón Rodríguez‐González, Irene Bretón Lesmes, María Teófila Vicente-Herrero, Jesús Sánchez-Díaz, Tomás Gómez‐Gascón, M. Canela, Ángel Asúnsolo   +32 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Are estimands being correctly used? A review of UK research protocols

Trials
Background The use of estimands in clinical trials was formalised with the adoption of the final International Conference on Harmonisation E9 Addendum on Estimands and Sensitivity Analysis in Clinical Trials (ICH E9(R1) Addendum) in November 2019.
Timothy P. Clark, Richard H. Wicentowski, Suzie Cro, Matthew R. Sydes, Brennan C. Kahan   +4 more
doaj   +1 more source

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials [PDF]

, 2017
Kedar Mahajan, Daniel Ontaneda
openalex   +1 more source